Lisata Therapeutics Inc.
January 22, 2025 - by Joey Ramson
$LSTA is the biggest laggard in the Prism MarketView Biotech index today after the cancer drug developer shared results from a mid-stage trial for certepetide, in patients with metastatic pancreatic ductal adenocarcinoma.
